ERBB2 and breast cancer: The median PFS for patients by molecular subtype was 36 months (IQR: 12–38 months) for HR+/HER2‐ breast cancer, 57 months (IQR: 9–59 months) for HER2+, and 5 months (IQR: 2–5 months) for TNBC (Figure 2D).